上海凯利泰医疗科技股份有限公司 审计报告 大华审字[2024]0011002303 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） ［右键单击上一行首，选择更新域键入公司名称的全称］ ［右键单击上一行首，选择更新域键入公司名称的简称］ 上海凯利泰医疗科技股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-019 上海凯利泰医疗科技股份有限公司 关于确定董事长薪酬的公告 以上确定董事长 2024 年度薪酬经董事会审议通过后，尚需提交公司股东大 会决议后方可生效实施。 二、独立董事过半数意见 公司 2024 年第一次独立董事专门会议审议通过《关于确定董事长薪酬的议 案》，全体独立董事一致同意将该议案提交第五届董事会第十四次会议审议，并 发表如下意见： 公司确定董事长薪酬系依据公司所处行业的薪酬水平结合公司实际经营情 况作出，符合公司目前经营管理的实际现状，有利于强化公司董事长勤勉尽责， 促进公司提升工作效率及经营效益，有利于公司持续稳定健康发展，不存在损害 公司及投资者利益的情况。 1 公司董事会对该议案的审议及表决程序合法、有效，因此，我们一致同意本 次确定的董事长薪酬，并同意提交公司 2024 年度股东大会审议。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 4 月 18 日，公司召开了第五届董事会第十四次会议，于 2024 年 4 月 19 日召开第五届监事会第十四次会议，审议并通 ...

上海凯利泰医疗科技股份有限公司 2023 年度内部控制自我评价报告 上海凯利泰医疗科技股份有限公司（以下简称"公司"）为了有效地开展公司经营活动， 控制经营风险，保护公司及投资者的合法权益，按照《中华人民共和国公司法》（以下简称《公" 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《企业内部控制基本规范》、 《深圳证券交易所创业板上市公司规范运作指引》等有关法律法规和规范性文件的要求，结 合自身经营管理特点和实际情况，不断完善公司治理，强化内控建设，有效防范了经营决策 及管理风险，保证公司规范运作和健康发展，保护投资者的合法权益。公司董事会对 2023 年度公司内部控制的规范性、完整性以及实施的有效性进行全面评估。 一、董事会对内部控制自我评价报告真实性的声明 建立健全和有效实施内部控制，评价其有效性，并如实披露内部控制评价报告是公司董 事会的责任。监事会对董事会建立和实施内部控制进行监督。管理层负责组织领导公司内部 控制的日常运行。本公司董事会及全体董事保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司内部控制的目标是合理 ...

上海凯利泰医疗科技股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2024]0011009727 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 上海凯利泰医疗科技股份有限公司 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 控股股东及其他关联方 资金占用情况的专项说明 大华核字[2024] 0011009727号 上海凯利泰医疗科技股份有限公司全体股东： 根据中国证券监督管理委员会发布的《上市公司监管指引第 8 号 ——上市公司资金往来、对外担保的监管要求》（证监会公告[2022]26 号）和深圳证券交易所《深圳证券交易所创业板上市公司自律监管指 南第 1 号——业务办理（2023 年 2 月修订）》的规定，就凯利泰编制 的 2023 年度非经营性资金占用及其他关 ...

Financial Performance - In 2023, the company achieved operating revenue of RMB 956.26 million, a decrease of 17.99% compared to the previous year[6]. - The net profit attributable to shareholders was RMB 112.54 million, an increase of 628.78% year-on-year[6]. - The decline in revenue was primarily due to the implementation of the national volume-based procurement policy affecting the sales prices of orthopedic products[6]. - The company fully recognized goodwill impairment of RMB 197.99 million from the acquisition of Aideer in the previous year, contributing to the significant profit increase in 2023[6]. - The report indicates that the overall operating performance showed substantial changes compared to the same period last year[6]. - The company's operating revenue for 2023 was ¥956,259,537.45, a decrease of 17.99% compared to ¥1,166,042,082.06 in 2022[23]. - Net profit attributable to shareholders was ¥112,537,303.89, a significant increase of 628.78% from a loss of ¥21,282,494.18 in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥61,648,763.58, up 327.50% from a loss of ¥27,098,445.37 in 2022[23]. - Cash flow from operating activities was ¥274,260,691.58, representing a 15.84% increase from ¥236,756,963.51 in 2022[23]. - Basic and diluted earnings per share were both ¥0.1570, a 630.41% increase from a loss of ¥0.0296 in 2022[23]. - Total assets at the end of 2023 were ¥3,354,004,114.33, a decrease of 1.70% from ¥3,412,148,611.26 at the end of 2022[23]. - Net assets attributable to shareholders increased by 4.39% to ¥2,859,842,987.33 from ¥2,739,569,604.96 in 2022[23]. - The company reported a quarterly revenue of ¥294,401,832.83 in Q1 2023, which decreased to ¥213,839,891.49 in Q3 2023[26]. - The company experienced a net profit of ¥74,900,497.03 in Q1 2023, which turned into a loss of ¥16,629,549.62 in Q4 2023[26]. - In 2023, the company reported a total profit of 50,888,540.31, a significant increase from 5,815,951.19 in 2022, marking a year-over-year growth of approximately 775.5%[31]. - The company received government subsidies amounting to 23,359,830.49 in 2023, compared to 22,158,373.72 in 2022, reflecting a growth of about 5.4%[31]. Business Operations and Strategy - The company plans to continue monitoring the impact of procurement policies on its business operations and adjust strategies accordingly[7]. - The company is undergoing changes in accounting policies due to new regulations effective from January 1, 2022, impacting financial reporting[24]. - The company is committed to continuous development in minimally invasive orthopedic medical devices, covering multiple product lines including spinal and trauma products[35]. - The company is navigating regulatory challenges and opportunities presented by recent healthcare reforms, which are reshaping the competitive landscape in the orthopedic medical device sector[36]. - The company plans to enhance its product innovation in orthopedics, focusing on new materials and technologies, while also expanding its business lines to mitigate the negative impacts of procurement policies[42]. - The company is actively developing a diversified medical device distribution service platform to improve its market share and influence in the medical device sales sector[48]. - The company aims to implement a "one invoice system" sales model targeting large hospitals, in line with national medical reform policies[48]. - The company is focusing on innovation in orthopedic products and expanding its international market presence[62]. - The company is implementing cost control measures to enhance profitability, including reducing labor costs and optimizing production processes[62]. - The company is expanding its product specifications to meet market demands, enhancing competitiveness in the orthopedic and neurosurgical product lines[92]. - The company plans to pursue capital expansion strategies through acquisitions and investments in related medical device companies, particularly in the minimally invasive orthopedic field[135]. - The company will enhance its multi-brand strategy by integrating existing sales channels and strengthening collaboration across product lines, aiming to establish a diverse sales network targeting hospitals[136]. - The company plans to accelerate the internationalization strategy, focusing on the PKP/PVP and Elliquence product lines, with dedicated management roles for foreign trade development in various countries[137]. Market and Industry Trends - The orthopedic implant medical device industry is experiencing rapid growth, with domestic companies benefiting from market expansion and import substitution[36]. - The average price reduction in orthopedic trauma medical consumables during centralized procurement reached 88.65%, significantly impacting industry expectations[37]. - The average price drop for selected orthopedic spinal consumables in centralized procurement was 84%, effective from January 2023[39]. - The national centralized procurement for high-value medical consumables, including artificial crystals and sports medicine supplies, resulted in an average price drop of 74% for sports medicine consumables[40]. - The implementation of bulk procurement policies in the orthopedic consumables sector is expected to significantly reduce patient financial burdens and standardize medical practices, leading to the gradual elimination of smaller, less innovative companies[41]. - The medical device industry is facing challenges due to policies aimed at controlling medical insurance costs, which may limit the growth of medical device expenses in healthcare institutions[130]. - The implementation of volume-based procurement policies is expected to increase pressure on pharmaceutical companies while also improving the quality and competitiveness of the medical industry[132]. - Increased competition in the orthopedic market is anticipated, necessitating timely product innovation to maintain profit margins[146]. Research and Development - R&D investment totaled 60.35 million yuan, a decrease of 8.30 million yuan or 12.09% year-on-year, with R&D expenditure accounting for 6.31% of current revenue, an increase of 0.42 percentage points[69]. - The company authorized 37 patents during the reporting period, including 5 invention patents, emphasizing its commitment to intellectual property management[69]. - The number of R&D personnel increased to 104 in 2023, a rise of 25.30% compared to 83 in 2022[93]. - The proportion of R&D personnel with master's degrees increased by 180.00%, from 5 in 2022 to 14 in 2023[93]. - The company is focusing on optimizing its surgical instrument packages based on clinical feedback, which is expected to improve operational efficiency[93]. - The company aims to strengthen its research and development capabilities, focusing on minimally invasive orthopedic surgical products to maintain a competitive edge in the market[134]. Acquisitions and Investments - The company has successfully integrated its product lines and sales channels following the acquisition of Aideer, optimizing its offerings in orthopedic implants and surgical instruments[46]. - The acquisition of Elliquence, LLC has allowed the company to expand into new business areas, particularly in surgical energy platforms and high-value consumables, enhancing its market presence[47]. - The company acquired a 56% stake in Jienuo Medical, enhancing its market competitiveness and operational efficiency in the medical sterilization service sector[50]. - The company completed the acquisition of 100% equity in Elliquence, LLC for approximately $77,152,000 (about ¥49,500 million) as part of its internationalization strategy[1]. - The company completed the acquisition of 100% equity in Jiangsu Aidi Medical Technology Co., Ltd., enhancing its market position[120]. - The registered capital of Jiangsu Aidi was increased from 60 million yuan to 110 million yuan, reflecting the company's commitment to growth[121]. - The company invested 15 million yuan in the Shanghai Hongsheng Houde Private Equity Investment Fund and 10 million yuan in Dongzhi Medical, among other investments, to enhance its industry presence[72]. Governance and Compliance - The financial report was confirmed to be accurate and complete by the board of directors and management, with no significant discrepancies noted[4]. - The company has established independent financial, operational, and personnel systems, ensuring no interference from existing shareholders[183]. - The company has implemented information disclosure management systems to ensure transparency and timely communication with stakeholders[170]. - The company respects and protects the rights of all stakeholders, promoting sustainable and healthy development[171]. - The company has conducted 1 annual and 1 extraordinary shareholders' meeting during the reporting period, ensuring compliance with legal requirements[163]. - The company maintains strict compliance with the "Investor Relations Management System" to ensure effective communication with investors[172]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[168]. Future Outlook - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[190]. - The company is investing 368.4 million in research and development for new technologies and products in the upcoming year[191]. - Market expansion efforts are focused on increasing presence in Southeast Asia, with a target of capturing an additional 10% market share by 2025[192]. - New product lines are expected to launch in Q3 2024, which are anticipated to contribute an additional 5% to overall revenue[194]. - The company has set a goal to reduce operational costs by 10% through efficiency improvements and technology integration[197]. - The company aims to enhance customer engagement through digital platforms, expecting a 30% increase in online interactions[200]. - Future guidance indicates a focus on sustainability initiatives, with a commitment to reduce carbon emissions by 20% over the next five years[200].

2023 年度独立董事述职报告（鲁旭波） 2023 年度，本人作为上海凯利泰医疗科技股份有限公司（以下简称"公司"） 的独立董事，在职期间本人严格按照《上市公司独立董事规则》《上市公司独立 董事履职指引》《深圳证券交易所创业板股票上市规则》《上市公司自律监管指引 第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》及《公司 章程》等规定，在 2023 年度的工作中，诚实、勤勉、独立的履行职责，积极出 席公司 2023 年度召开的相关会议，与公司管理层保持沟通交流，认真阅读会议 相关材料，认真审议董事会上的各项议案，对公司重大事项发表了独立意见，切 实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事的作用。现将 2023 年度本人履行独立董事职责工作情况汇报如下： 一、 独立董事的基本情况介绍 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。本人履历如下： 鲁旭波先生，1980 年 3 月出生，中国国籍，无境外居留权，本科学历。2005 年 12 月至 2016 年 6 月任职于浙江康盛股份有限公司，历任董秘助理、证券事务 代表、投资部经 ...

上海凯利泰医疗科技股份有限公司 未来三年（2024-2026 年）股东分红回报规划 为完善和健全上海凯利泰医疗科技股份有限公司（以下简称"公司"）利润 分配政策，建立健全科学、持续、稳定的分红决策和监督机制，增加利润分配决 策的透明度和可操作性，积极回报投资者、充分保障投资者的合法权益，引导投 资者树立长期投资和理性投资理念。根据中国证监会《关于进一步落实上市公司 现金分红有关事项的通知》（证监发[2012]37 号）、《上市公司监管指引第 3 号— —上市公司现金分红（2023 年修订）》（中国证券监督管理委员会公告[2023]61 号）和《公司章程》等相关文件、制度的规定，并综合公司未来的经营发展规划、 盈利能力、现金流量状况等因素，制定了《未来三年（2024-2026 年）股东分红 回报规划》（以下简称"本规划"），具体内容如下： 一、 公司制订股东回报规划考虑的因素 公司制定本规划着眼于公司的长远和可持续发展，综合考虑公司的盈利能力、 经营模式、发展阶段、投资资金需求、现金流状况、股东回报、社会资金成本及 外部融资环境等因素，平衡股东的投资回报和公司未来发展的资金需要，建立科 学、稳定、持续的利润分配 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-014 上海凯利泰医疗科技股份有限公司 关于向多家银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司(以下简称"公司")于 2024 年 4 月 18 日召开第五届董事会第十四次会议，审议通过了《关于向多家银行申请综合授信 额度的议案》，本事项尚需提交股东大会审议。现就相关情况公告如下： 根据公司经营发展的需要，为保证公司及公司全资、控股子公司现金流量充 足，公司（含全资子公司和控股子公司）预计向多家合作的商业银行申请总额不 超过人民币 8 亿元的综合授信（最终以各家银行实际审批的授信额度为准），用 于流动资金贷款、开立银行承兑汇票、信用证、商业承兑汇票贴现等，授信期限 为 1 年，授信期限内额度可循环使用。 上述授信总额度不等于公司的实际融资金额，实际借款金额应在授信额度内 以相关银行与公司及公司全资或控股子公司实际发生的贷款金额为准。公司管理 层可根据经营情况增加授信银行范围，调整银行之间的授信额度。 上述银行综合授信事项授权期限自股东大会 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-011 上海凯利泰医疗科技股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日以邮件方式向公司各监事发出关于召开第五届监事会第十四次会议的通知。 2、公司于 2024 年 4 月 19 日 10 时 30 分以现场结合通讯方式召开监事会。 3、本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。 4、会议由周志强先生主持，公司董事会秘书列席本次会议。 2023 年度，公司监事会在董事会和公司各级领导的支持配合下，严格按照 《公司法》《证券法》《公司章程》及《监事会议事规则》等有关规定的要求，认 真履行监督职责，切实维护公司利益和股东权益，对公司的生产经营活动、重大 事项、财务状况以及董事、高级管理人员履行职责情况进行了监督和检查。 表决结果：本议案以 3 票同意、0 票反对、0 票弃权获得通过。本议案尚需 提交公司股东大会审议。 1 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-020 上海凯利泰医疗科技股份有限公司 关于召开2023年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开本次会议的基本情况 1、股东大会届次：2023年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法性及合规性：公司第五届董事会第十四次会议审议通过 了《关于提请召开公司2023年度股东大会的议案》，本次股东大会会议的召开符合 有关法律、行政法规、部门规章、规范性文件和公司章程等规定。 4、会议召开日期和时间： （1）现场会议时间为：2024年5月22日（星期三）14时50分 （2）网络投票时间：2024年5月22日。其中，通过深圳证券交易所交易系统 进行网络投票的时间为：2024年5月22日上午9:15—9:25、9:30—11:30，下午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的时间为：2024年5月22 日上午9:15至下午15:00。 5、会议召开方式： 本次股东大会采用现场投票、网络投票相结合的方式召开。公司将通过深圳 证券交易所交 ...